论文部分内容阅读
Objective: This prospective biomarker study in patients (pts) with mRCC treated with the programmed death-1 (PD-1) inhibitor antibody nivolumab assessed baseline (BL) and changes in serum chemokines,tumor T cell infiltrates (TIL), gene expression, T cell repertoire (TCR), and other biomarkers potentially associated with clinical outcomes (NCT01358721).